MiMedx Group Q3 2024 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $84.057M Beat $82.700M Estimate
Portfolio Pulse from Benzinga Newsdesk
MiMedx Group reported Q3 2024 earnings of $0.07 per share, surpassing the $0.04 estimate, and sales of $84.057M, exceeding the $82.700M estimate. This marks a 40% increase in EPS and a 2.87% rise in sales compared to the previous year.
October 30, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MiMedx Group's Q3 2024 earnings and sales exceeded analyst expectations, with EPS at $0.07 and sales at $84.057M. This strong performance indicates positive momentum for the company.
MiMedx Group's earnings per share and sales both exceeded analyst expectations, indicating strong financial performance. The 40% increase in EPS and 2.87% rise in sales compared to last year suggest positive growth, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100